Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Have you read any of EquityElite's posts? Gsdubb's? Investaholic's? Andyshow's? InvestorStemCell's? Any of these contributors consistently have provided a logical rationale for, not just buying the stock, but holding onto it. You may not agree, and that is certainly your perogative...but I do.
I know...it's very amusing to see a company struggling to obtain funding and survive while its mission is to rid the world of pain and suffering. Very funny stuff for sure...just my .002 cents worth.
And who has suggested that we aren't...there are many investors here that own in surplus of 1 million shares of Bioheart stock, at sub-penny prices. Gypsydoc, I also believe the future of this company is in the human regenerative space...there certainly is attractive potential with animal treatments, but Bioheart has never been just about money to me...what first attracted me, and still does, is the potential to help millions of people suffering from horrific illnesses that only stem cells can cure. I would be disappointed if the mission to help, possibly alleviate, hardship and suffering of countless people around the world is de-railed due to financial considerations alone.
I always appreciate and respect your analysis, InvestorStemCell. A question for you... How would a reverse split be of benefit to a long investor, as I am, when the quantity of shares I hold would be decreased substantially? I understand the potential immediate impact to the company, but the individual investor loses the multiplying power of owning numerous shares. As always, I look forward to your explanation. Thank you in advance.
Could bankruptcy happen? Yes, that is always a potential outcome. Do I believe it will occur...no, I do not. Why? I believe in the management of Bioheart...I believe in their strategy to increase revenue by growing our subsidiaries...I believe in the science. I still own every single share I've ever purchased...I still believe.
I feel like I'm reading Tolsoy's War and Peace...could you provide the CliffsNotes version please...I'm busy. Thanks.
I also agree...I don't believe a reverse split would be the best course of action. Yes, there would be some immediate benefit, but often, the share price decreases over time anyway....and then shareholders are left holding a significantly less quantity of accumulated shares (please correct my analysis if mistaken). I much prefer the success of the current plan that is in place...grow revenue from the subsidiaries (US StemCell Clinic and Training, and VetBioligics) and use the monies to fund AdipoCell coming to market in 2017 for CLI and the Marvel trial for MyoCell to be approved by the target date of 2019. Just my opinion.
That was a well-reasoned response...nicely done.
Awesome...very well done. Your analysis is thoughtful and reasonable...why your voice on this forum is one of several I respectfully listen to. Again, thank you.
I have been giving something that was eluded to in the recent shareholders' conference call considerable thought regarding the timeline to market for MyoCell.
If the target date is for a 2019 launch, then the BLA would need to be filed by, at a minimum, 2018 (providing at least a year for processing and reply to Bioheart of filing status). That would mandate the Marvel trial be fully enrolled and completed by 2017, giving opportunity for 6 month data required for the primary safety and efficacy endpoints, as well as an additional 6 months for 1 year markers. For this to take place during the proposed timeline, Marvel enrollment would have to re-commence in 2016...which means, referring to your post, the financing must be in place this year. I believe all of what is needed monetarily has been carefully thought out prior to making comments public regarding dates for market approval ...with the past level of scrutiny Bioheart has been receiving, what would the benefit be otherwise to invite negative perception. Your thoughts?
"OK? So this is a "fake" free market share price and not the "real" imaginary, make up a wish price of .20 "minimum"?? "
"How does that work exactly? A FREE MARKET where shares are bought and sold based on supply and demand is FAIRLY PRICING a stock right now at about .009, aka 9/10ths of ONE CENT. Buyers and sellers are trading actively in real time paying .009 or so, but that's the "fake" price and it should really be like 20X more at .20 "minimum"?? Wow !! "
I plan to reference these comments when the stock price hits $1.
Bioheart Touts 2014 Accomplishments; Seeks More in 2015
7 minutes ago
????
SUNRISE, FL / ACCESSWIRE / March 17, 2015 / Bioheart, Inc., a Florida Corporation (BHRT), an emerging enterprise in the regenerative medicine / cellular therapy industry is pleased to announce, following the release of its Form 10-K Annual Report, key 2014 accomplishments including but not limited to:
1. A 2,040% increase in year over year revenues to $2.1 million in 2014 from $0.1 million in 2013,
2. A 28% decrease in year over year net loss to ($2.25) million in 2014 from ($3.14) million in 2013,
3. A 42% decrease in year over year cash used in operating activities to $1.1 million in 2014 from $1.9 million in 2013,
4. A 20% reduction ($2.3 million) in year over year current liabilities to $11.1 million at December 31, 2014 from $13.4 million at December 31, 2013, and
5. A 20% reduction in the Company's working capital deficit.
"Bioheart is moving in the right direction," said Mike Tomas, President and Chief Executive Officer. "We are extremely proud of what we have accomplished in 2014 and through an extraordinary effort have set the stage for continuing improvements in both income statement and balance sheet performance in 2015. In 2015, we will continue our efforts to reshape Bioheart into a growth oriented, profit generating company capable of delivering regenerative / cellular therapies and products globally while advancing our clinical development pipeline to market. In the coming months, we look forward to announcing new strategic relationships that will introduce new opportunities for growth as well as jump starting long delayed clinical programs. I extend my sincere thanks to Dr. William P. Murphy, Jr., our Chairman, our Board of Director, Kristin Comella, our Chief Scientific Officer, the Bioheart Team and most especially you, our shareholders for your continuing support, commitment and dedication to our Company. We are excited about Bioheart's future and we look forward to keeping you posted on our progress."
"what dilution?...BHRT must have LOTS OF $.....as I see Thomas paid himself a raise and bonus (1 mil a yr) ...huge red flag when he did that!...I lost respect for him when he did it especially if he truly believed that he was on the cusp of huge revenues returns then he could compensate himself and management AFTER those returns we realized. He would have been a hero .....instead he hedged his bets and took the easy money...Not impressed with any of them....or their ethics!!"
Then, if you currently own shares in Bioheart, I suggest you sell them. There are numerous investors that would be grateful for the opportunity to accumulate more. I have absolutely no concerns over the leadership team increasing their deserved compensation...none.
"An easy fix for the financial issues would be for Mike Tomas to give some money back to the company. If I were in his position I would save that type of compensation until the company could afford it."
Respectfully, as a shareholder of Bioheart since 2008, I am grateful you are not in his position. I voted for his raise, and would do so again. His salary, as well as Ms. Comella's, is not a concern of mine...outside entities that influence the stock price are.
Firstly, thank you for your reply and commentary regarding stock reverse splits...much appreciated. Secondly, when do you believe detailed information from the court hearing will be available, including repercussions if due? Again, thank you in advance for your reply.
InvestorStemCell...I very much respect your analysis and have a fundamental question for you regarding Bioheart and the potential for a reverse split of our stock in the future. First and foremost, do you believe this will occur, and secondly, would it be in the best interest of Bioheart's shareholders? I understand the temporary benefit with an increase in share price but I'm not persuaded that this potential move would alleviate investor concerns...from what I've read, it may exacerbate them to some degree. Your thoughts? Thank you in advance for your reply.
"I was under the impression the sales force was specific to an individual business...great news if I was incorrect. The more focused an effort promoting the 'revenue stream' for Bioheart, the better. Where did you hear the sales force was to promote all three business models? Thank you in advance for your reply."
I am re-posting this as I'm still awaitng a reply...if I have missed one, then my sincere apologies. I welcome anyone to supply the answer. Thank you.
I was under the impression the sales force was specific to an individual business...great news if I was incorrect. The more focused an effort promoting the 'revenue stream' for Bioheart, the better. Where did you hear the sales force was to promote all three business models? Thank you in advance for your reply.
In my opinion, it is very simple now...a specific plan has been laid out in a shareholder's briefing describing the company's intentions and strategies moving forward. Investors will either believe that to be enough, or not. I personally believe it to be more than adequate and will continue to hold my shares and anticipate future success. Those that feel differently are certainly free to do so...we will all find out together soon enough, and at the same time, who was right in their analysis.
I have also hoped, if there were to be a merger in Bioheart's future, for J&J to be the partner. There are several connections that could provide incentive to do so:
1. Mr. Murphy, his past success with Cordis alone would be an important benefit
2. MyoStar catheter being utilized in several of the clinical trials
3. J&J's business model allows for incoming companies to retain their autonomy...in my opinion, Mr. Tomas should always remain on the management team as his quality leadership and expertise are unrivaled
4. J&J is in need of a quality flagship business in the biopharmaceutical/pharma sector...Bioheart would be an amazing addition to what they already do have, and fill a current void
This is conjecture on my part, and certainly only an opinion, but if Bioheart were to merge with, or be acquired by another entity, this would be an amazing opportunity for all involved.
I did...via regular postal delivery.
I happened to enjoy it...thank you Gsdubb. Merry Christmas and a Happy New Year to all who take their time to post on this board (and yes, that includes you Hopalong).
You are correct...but let me get ahead of the post that 'someone' will make concerning this PR. "Yeah, but it's just another PR in a long list of PRs...what about the SEC documents; they are the only thing that matters. And how is one office and 2 doctors going to treat all of Australia...those millions of patients aren't going to go into that one tiny office, are they. Very misleading PR...and then there are the physicians...neither one is qualified because of 'fill in the blank here'...not impressed. All in my opinion, of course."
I, however, am impressed. Great news for a great company...once again Bioheart is trying to make a difference where none have been able to do so...and in the backyard of Mesoblast!
To some, I don't believe it would matter if there was a joint venture announced with a major pharmaceutical company, that all debt has been accounted for, or Kristin Comella was just awarded the Nobel Prize for her work with stem cell biology, the commentary would still be the same..."wow, hard to believe...blah, blah, and blah". I only hope what is obvious to me is evident to all...there is nothing Bioheart can do, financially nor scientifically, that will change the narrative...nothing. This fact keeps me from over-reacting to constant negative analysis...it doesn't deter me at all. Only a Bioheart bankruptcy will do that...and I don't believe that will happen.
Great find... an honest and unbiased assessment as to the industry and its current major players. To me, very encouraging having Bioheart on the list...yes, I know, it is a penny-stock, now. But it hasn't always been so...I still have shares I bought at $5. Why have I not sold them...that is very easy to answer. I believe to the very core of my being that Bioheart will not just go back to its IPO share price, but will surpass it. Call me naive, financially foolish, etc. I believe in this company since my research discovered what was possible over 10 years ago...I still believe, and will continue to do so until a reason to do otherwise.
Thank you for the post...I've mentioned previously that, if possible, Bioheart list on the CalXStars stock exchange. It is designed very much for a company like ours to get the much needed capital to be successful...and the positive of not having to deal with the constant manipulation of the stock (shorting is prohibited). Only people that have Bioheart's best interests at heart are allowed to participate. Again, not certain if this is possible...just a thought.
Great question...I'm looking forward to the reply.
I haven't posted on this board in a VERY long time...but I have to say thank you for your comment. I'm patiently awaiting the time this nonsense ends...and then I may return once again as a regular contributor. Again, I appreciate your insightful analysis...well done.
"That is the reality. Despite the big boasting of "revenue" blah, blah"
Funny, that is just what I was going to write...blah, blah, blah.
"Yeah, DOWN 5+ percent now on a 13% wide spread- that's a great "direction". +8% on no vol, then down 5% in a blink.
Wait for the down 20% day, it's coming IMO if the 3 month chart is any indicator. They recently dumped it to below the 200 DMA (.021) on extremely high vol, and it happened in a blink. Swings of 50% to almost 100% losses in a matter of a few trading days- amateurs getting cleaned out to unload shares for some "big boy" who's holding 10 million or whatever and is probably making at least double their money on those shares they got at 1 cent or 1.5 cents.
Anyone buying at above those .03 tops, now needs 50% of greater gains just to break even, many of them losing that much in a few hours, maybe one trading day. Great "direction". .038 a few trading days ago to .025 a few days later. Great.
Yeah, a Youtube video with 154 "views" or whatever it is, that's how you build large, successful, public traded companies? Oh, "LOL"."
LOL!
""OLD" is an opinion. It's an OLD video to me and the info in it is also same OLD, same OLD as in nothing "new". It's a qtr ago, that's OLD NEWS IMO, especially in the tech world.
It would be labeled a "past" video from April 2014. Not "new". New is today, yesterday, maybe this past week. That's "new"."
Old is an opinion...and so is new. Am I missing someting here?
Very well stated...and I believe it is possible that we may all be under-emphasizing what may be forthcoming. I am still of the persuasion that what may prove to be a/the relationship that takes Bioheart to a level that's currently unimaginable is with BioLeonhardt and CalXStars. Call it a hunch, or if you prefer, maybe just unbridled optimism, but if Bioheart was listed on the California Stock Exchange at some point in the future, which is being developed for companies just like Bioheart to create a stable and growing financial environment, the removal of impediments for busting through the 'single dollar' ceiling could indeed be a reality. I believe this is a potential reason why Mr. Leonhardt resigned his post and started the referenced endeavors... but please note, I have nothing to base this assumption on other than my privately-held belief. And what if the future plan is an incorporation of all stem cell-types for the treatment of multiple conditions under a singular entity. Bioheart had its beginning with the narrow focus of cardiovascular diseases, because they are the most prevalent and promising world-wide. With the recent discoveries revolving around AdipoCell, the focus has shifted to other conditions involving other systems...oncology, ophthalmology, endocrinology, and respiratory (to name a few). Is it possible that something far greater is being considered than we're even visualizing? Again, this is simply conjecture on my part... but this is also why I am in this for the 'long-haul'. What we're discussing here could be one of the greatest business stories ever told...yes, I know, it's a penny-stock. But it wasn't always so...Bioheart was listed at one point on the NASDAQ for approximately $5/share...I still currently own some of those shares. I also own a considerable amount in the penny range. Why? For the same reason...I believe in this company...the technology, the management, the vision, the real possibility of truly eradicating horrific suffering in the world. To me, this is not about a buck here or a couple of bucks there...this is about being part of something that can truly make a positive difference in the world. First comes the idea followed by a plausible vision...then, with time and persistent endurance, comes success...and that's what I'm waiting for.
Very well done, pijoe. I believe you've formed a very cogent analysis of something that has been discussed here generally, for some time...and specifically as of late. If a business, or company, stands to benefit or profit from a successful enterprise, then it's just common sense to know another will not. That is why competition evolves using various methods to alter the course of that business. After a launch of a viable product or service this is mostly done in the field...before marketing, it is done in places like here...in the arena of ideas. There are, I believe, obvious and coordinated efforts to alter the course of Bioheart....it is and has been obvious to all for some time now. If Bioheart succeeds, other companies will have failed to be the first to an untapped and unlimited market...one that has the attention of academia and large pharmaceutical and device companies. I know this to be true...and so I am not the least bit persuaded by the constant drumbeat of 'dire' commentary...that is what a competitor does...some are just, shall we say, more energetic and persistent. If Bioheart does, as I suspect they will, get MyoCell to market first, the battlefield may change, but our opposition will only intensify. That is because so very much is at stake..and why we must win!
Yes...very insightful post. The science, or technology, is always the key ingredient in a biotech company. Does the financial picture need to be positive...absolutely! There is no debate regarding that matter. The disagreement on this board is generally when does that picture need to be a crystal clear one. Most here feel it is not yet imperative for all the financials to be resolved for Bioheart to eventually be a success. Time is on our side...we are currently in the lead when it comes to a Phase 3 clinical trial, and doing so with superior results to any and all competitive cellular or device therapies (MyoCell nearly DOUBLES the closest challenger).
Also a very good piece of information...thank you.
Thank you Gsdubb...I had forgotten that valuable piece of information.
Thank you for the video BioheartUS...even though it was several years old, it was still insightful as to the desired financing required to bring our flagship product to market. If I may, I have an additional question for you to ask Ms. Comella...would she be attending/presenting at the CRF Cell Therapy Conference in New York in January 2015? I am considering attending and was hopeful she would be as well, giving an update as to the developments of Bioheart's product line. Dr. Warren Sherman, a key figure involved with the conference, spoke this year regarding the Marvel trial. Thank you.
Thank you for your reply...I will gladly do so.
Thank you for your very informative post... I was aware of the SDF-1 technology and excited for what it could mean for the health of heart failure patients. I'm also impressed with your efforts to improve upon a therapy that itself has the potential to revolutionize cardiovascular medicine. If I may ask a few questions to help clarify some confusion I have had regarding the REGEN and MARVEL Trials...is REGEN still enrolling patients or were those patients put into the Marvel 2 program (it has been my understanding that this was indeed the case, and partly as to why the MIRROR Trial was initiated)? In addition, is it possible at this time for you to give an approximate target date for market approval regarding the first generation MyoCell product and which trial will be the pivotal one responsible for approval? It is understandable if these questions cannot be answered in detail at this time, but I felt comfortable in asking and would be grateful for any insight you may offer. Thank you in advance for your reply.
BioheartUS...thank you for your message and for all you do. I have been following Bioheart as an interested observer for over 10 years now, and have been an investor since its IPO in 2008. Please know how truly grateful the investors are for your wonderful company... for what you do , and also for what you hope to do. I'm certain I speak for more than just myself when I wish you continued success in your endeavor to bring therapies to market that will change the lives of multitudes of people worldwide. I am praying for Bioheart's success and for your patient endurance through the inherent difficulties of doing so...stay the course; many lives are depending on it.
AdipoCell is the 12-month Angel Trial, is it not?